Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
You may also be interested in...
Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.
Bystolic Approved; Forest Prepares To Launch In Crowded Beta Blocker Market
Firm hopes nebivolol's subgroup efficacy will set the novel beta blocker apart from others in its class.
Forest/Mylan Respond To FDA “Approvable” Letter On Nebivolol
Forest estimates review of the novel hypertension drug could take six months.